1. Home
  2. PZZA vs ABCL Comparison

PZZA vs ABCL Comparison

Compare PZZA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Papa John's International Inc.

PZZA

Papa John's International Inc.

HOLD

Current Price

$32.19

Market Cap

1.0B

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$3.75

Market Cap

910.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZZA
ABCL
Founded
1984
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
910.0M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
PZZA
ABCL
Price
$32.19
$3.75
Analyst Decision
Buy
Buy
Analyst Count
8
5
Target Price
$45.00
$7.75
AVG Volume (30 Days)
1.3M
3.8M
Earning Date
05-25-2026
05-26-2026
Dividend Yield
5.87%
N/A
EPS Growth
N/A
10.91
EPS
0.90
N/A
Revenue
$2,068,421,000.00
$75,128,000.00
Revenue This Year
$1.13
N/A
Revenue Next Year
$0.96
$6.30
P/E Ratio
$34.62
N/A
Revenue Growth
14.07
160.56
52 Week Low
$30.16
$1.89
52 Week High
$55.74
$6.52

Technical Indicators

Market Signals
Indicator
PZZA
ABCL
Relative Strength Index (RSI) 41.61 59.75
Support Level $30.18 $3.37
Resistance Level $40.23 $3.84
Average True Range (ATR) 1.59 0.22
MACD 0.07 0.09
Stochastic Oscillator 37.75 99.44

Price Performance

Historical Comparison
PZZA
ABCL

About PZZA Papa John's International Inc.

Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: